Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Double doses of clopidogrel better than standard doses for angioplasty patients

This article was originally published in Clinica

Executive Summary

High doses of the antiplatelet drug clopidogrel significantly reduce complications in patients undergoing angioplasty, a trial reported at the ESC meeting has found. The CURRENT-OASIS 7 study assessed 17,000 patients who underwent angioplasty having been randomly assigned to receive either the high dose: 600mg of clopidogrel on the first day, then 150mg once a day for seven days, followed by 75mg daily until day 30, or the low dose: 300mg on day one, followed by 75mg once a day until day 30. The more intensive regimen reduced the risk of stent thrombosis and heart attack by 30% and 22%, respectively, compared with the standard regimen in 68% of patients. There was an increase in major bleeding, but no increase in bleeds into the brain or those that were fatal.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel